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Using neutron diffraction as a probe, investigations at the interface between physics,
chemistry and medicine can provide major information to clinicians, and the goal of this
short review is to assess different information which can be retrieved. Varied research
issues can be approached, such as the interaction of tissues with trace elements, the
mechanical deformation of prosthesis, and the effect of diseases affecting bone or kidney
stone composition and microstructure, as well as the dissolution process induced by drugs
on kidney stones.
© 2015 Académie des sciences. Published by Elsevier Masson SAS. This is an open access
article under the CCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Using neutrons as probes to investigate biological en-
tities has led to numerous signiﬁcant breakthroughs in
research ﬁelds at the interface between medicine, chem-
istry and physics [1e9]. The power of neutron investigation
comes from the unique physical properties of these parti-
cles, which are used through a vast array of techniques to
study different characteristics of matter in its various
forms.
Instrumental Neutron Activation Analysis (INAA) is for
example used to evaluate the concentration of trace and
major elements [10e28] in materials. Toxic elements,
such as As or Sb, can be detected in biological materials
with a lower limit close to 0.005 mg/g [23]. The content of
metals in various parts of the human brain has beeny).
ed by Elsevier Masson SAS.discussed [24,27], through the assessment of the rela-
tionship between the content of Al and Alzheimer's
disease [25].
Because of the neutron mass, the neutronwavelength is
comparable to interatomic distances in matter, and neutron
diffraction can be used to study crystal structures, that is,
the arrangement of atoms in a crystalline material. Such
information is of major importance in the case of implants
made of bioceramics for bone ﬁlling and replacement
[29e32]. More generally, because neutrons do not damage
biological materials, they offer the opportunity to investi-
gate bulk biological samples, whether as an aqueous solu-
tion, a solid, a powder, or a crystal. In addition, the neutron
carries a spin, allowing one to study the static and dynamic
magnetic properties of matter. As underlined by S.C. Vogel
[33], neutron scattering uniquely complements other
characterization techniques, and together with X-ray syn-
chrotron, is considered amongst the most useful micro-
scopic probes of matter available today.This is an open access article under the CC BY-NC-ND license (http://
Fig. 1. Neutron and X-ray scattering lengths for different atoms.
F. Damay et al. / C. R. Chimie 19 (2016) 1432e1438 1433The aim of this review is to give clinicians an overview
on how neutron diffraction can be used to study different
kinds of biological entities.
2. Neutronematter interaction: some basic notions
Neutrons do not exist naturally in free form, but decay
into protons, electrons, and anti-neutrinos. In order to
produce neutrons, two kinds of sources exist and are based
either on ﬁssion, in a conventional nuclear reactor, or on
spallation (neutrons are obtained by bombarding a target of
heavy elements with high-energy particles, typically,
accelerated protons) processes.2.1. Instrumental neutron activation analysis
When a sample is subjected to a high neutron ﬂux, it
emits gamma rays, following the decay of radioactive ele-
ments which have been produced. The energy and intensity
of these gamma rays are directly related to the nature and
concentration of the elements present in the sample. This
technique has been used to investigate different kinds of
biological entities, such as hair [13], liver [14], kidney
stones [15,21], gallstones [16], cortical and trabecular bones
[17,18,22], human prostate [19], human nails [20], human
thumbnails [26] or urine [28].
Several investigations have also been dedicated to kid-
ney stones [34,35]. C. Koeberl and P.M. Bayer [34] have for
example determined the presence of rare-earth elements
in brain tissues and in kidney stones. Rare-earth elements
have an exogenous origin, being mainly incorporated into
the human body via ingestion of food or by inhalation of
dust particles. The data suggest that rare-earth elements
are trapped in kidney stones, by a slow accumulation pro-
cess. In [35], D. Gompertz et al. have compared biochemical
indicators of renal dysfunction with liver and kidney cad-
mium levels measured by neutron activation analysis in a
group of 37 cadmium smelters.Fig. 2. (a) Schematic representation of the Bragg law in diffraction, 2dhkl sin
q ¼ l, relating the diffraction angle q, the beam wavelength l, and the space
between lattice planes (in thick dark lines) dhkl. (b) Rietveld reﬁnement
result of the NPD diagram of a cystine kidney stone (experimental data Yobs
in red, calculated proﬁle Ycalc in black, and YobsYcalc difference in blue). Tick
marks in green below the proﬁles indicate the peak positions of allowed
Bragg reﬂections for cystine.2.2. Neutron powder diffraction (NPD)
Scattering processes between neutrons and atoms are
also used by scientists to study matter [36e40]. Neutrons
are electrically neutral and interact only weakly with
matter, and have, as a result, a penetration depth of several
centimeters. Unlike X-rays, they do not interact with the
electronic cloud of an atom, but with its nucleus: the
strength and character of this neutronenucleus interaction
is characterised by the so-called neutron scattering length.
This parameter varies irregularly from one nucleus to
another. In particular, it is quite large for light elements like
hydrogen, carbon, nitrogen or oxygen, which are almost
invisible to X-rays (Fig. 1). Neutrons are thus an important
tool in the investigation of the location and dynamics of
protons, an essential aspect in many biological processes.
Elastic scattering, or diffraction, describes a process in
which the incident and the scattered neutrons have the
same energy. The scattering angle q (as deﬁned in Fig. 2)
gives information, through Bragg’s law, on the periodicity
of the atomic arrangement (i.e. crystal unit cellparameters). The intensity of the Bragg peaks is related to
the cell symmetry and atomic positions within the crystal
unit cell.
As shown in Fig. 2, a neutron powder diffraction (NPD)
pattern is simply a recording of the intensity of diffraction
(in neutron counts) versus the diffraction angle q.
A typical example of a neutron powder diffractometer is
the G4.1 instrument, located at the French neutron source
Orphee. The Orphee reactor produces a white neutron
beam (broad distribution of wavelengths) and a mono-
chromator is used to select the desired wavelength. The
monochromator is commonly a single crystal of germa-
nium or silicon; on the G4.1 beamline, a vertically focusing
pyrolytic graphite monochromator is used. The detector is
F. Damay et al. / C. R. Chimie 19 (2016) 1432e14381434an 800-cell multidetector covering a 2q range spanning 80,
which collects all reﬂections simultaneously, thus
increasing the data acquisition speed (Fig. 3).
Rietveld reﬁnement [41] is the most common method
used for the determination of crystal structures from X-ray
or neutron diffraction data. A theoretical diffraction pattern
is calculated based on a proposed model, and compared
with the experimental data. Gradual changes are intro-
duced into the model, to minimize the difference between
the observed and calculated patterns (Fig. 2). This is usually
performed using a computer software package such as
FullProf, Jana2006, or GSAS [41].
Rather straightforward experimentally, powder diffrac-
tion provides after data reﬁnement awealth of information,
not only about the detailed atomic arrangement, but also
about the size, the residual strains and the morphology of
the powder particles. For instance, the broadening of the
diffraction peaks can be the result of two physical factors,
either a small particle size or residual microstrain, whose
effects can be analyzed separately [42]. The size of nano-
crystals can therefore be estimated after analysis of the
peak proﬁles. This can be of clinical importance, as in [43],
in which U. Vetter et al. have pointed out signiﬁcant
modiﬁcations of the apatite crystal sizes in the bones of
patients with osteogenesis imperfecta.
Regarding the orientation of the nanocrystals within a
bulk material, diffraction also provides key information:
Bacon and Goodship [44] have shown through neutron
diffraction that the long bones of animals have the c-axes of
their apatite crystals preferentially oriented to withstand
stresses. Recent experimental developments combining a
monochromatic X-ray beam (<30 mm) with a charge-Fig. 3. Schematic representatiocoupled device camera allow a relatively easy quantiﬁca-
tion of crystal alignment in bone tissue [45].
3. Neutron scattering and kidney stones
Biological calciﬁed entities such as kidney stones show
several levels of organization. They result from an
agglomeration of crystallites of a few micrometers, each
crystallite being made of nanocrystals (whose dimensions
are about a few hundreds of nanometers, and can be
studied by neutron scattering). The deﬁnitions for the
terms ‘nanocrystals’ and ‘crystallites’ aremade according to
Van Meerssche & Feneau-Dupont [46].3.1. Cystine kidney stones
Recently we have published a neutron powder diffrac-
tion (NPD) and FE-SEM investigation on cystinuria [47].
Worldwide, the incidence of cystinuria is about 1:7000
births and represents a major medical problem, because of
stone recurrence and the risk to induce renal failure. This
genetic disease comes from a mutation in renal epithelial
cell transporters [48e53]. More precisely, two different
types of cystinuria may be distinguished according to ge-
netics: type A cystinuria, due to mutations along the
SLC3A1 gene encoding the rBAT heavy subunit, and type B
cystinuria, with mutations in the SLC7A9 gene encoding for
light subunit b0,þ AT [54]. In both A and B cystinuria, mu-
tations result in a deﬁcient reabsorption of the dibasic
amino acids and cystine [54,55]. The excessive amount of
cystine in urine leads to a high risk of cystine precipitation,n of the G4.1 beamline.
F. Damay et al. / C. R. Chimie 19 (2016) 1432e1438 1435and to the formation of stones as a consequence of the poor
solubility of this amino acid.
Regarding cystine kidney stones, two morphological
types, namely Va and Vb, exist [56e58]. The surface of the
ﬁrst kind of stone (type Va, Fig. 4a) is homogeneous,
granular, made of crystals with blunt angles, and is
commonly observed in untreated cystinuric patients.When
cystinuria is treated with alkali or/and thiol therapy, a
second type of cystine kidney stone may appear (type Vb,
Fig. 4b).
The salient point of this study comes from NPD, and lies
in the result that only the usual alkaline therapy with so-
dium bicarbonate reduces signiﬁcantly the growing pro-
cess of cystine crystals. All the other therapies, namely
alkalinization with other salts (Foncitril, Alcaphor, potas-
sium citrate) and thiol therapy (sulfhydryls) based on tio-
pronine, D-penicillamine or on captopril treatments, seem
inefﬁcient. A similar conclusion is obtained through FE-
SEM observations. In conclusion, all observations agree
that only the usual alkaline therapy with sodium bicar-
bonate reduces the size of both crystals and crystallites,
while othermedical treatments only alter the surface of the
crystallites.Fig. 4. (a) Va cystine kidney stone, (b) Vb cystine kidney stones. The cross-
section of a stone reveals a diffuse concentric structure at the periphery, and
an unorganized agglomerate of cystine crystals in the core, (c) typical
neutron diffraction diagrams of cystine kidney stones collected on the G4.1
beamline. (d) Broadening of a Bragg peak, corresponding to the decrease of
the crystallite size after treatment with sodium carbonate alkaline therapy,
which evolves from >200 nm (Va) to ~138 nm (Vb) [58].3.2. Calcium oxalate kidney stones
In western countries, calcium oxalate (CaOx) is the main
component of more than 70% of all kidney stones [59,60].
Among the different crystalline forms, calcium oxalate
monohydrate (COM e CaC2O4eH2O), or whewellite, is the
most frequent [61e63]. COM kidney stones are related to
hyperoxaluria (too much oxalate present in the urine),
while excess of calcium (hypercalciuria) in urine leads to
the formation of calcium oxalate dihydrate (COD e
CaC2O4e2H2O) [64]. Of note, a third species exists, namely
calcium oxalate trihydrate (COT e CaC2O4e3H2O e caox-
ite), which has been observede rarely e in patients treated
with drug containing a precursor of oxalate [65].
Hyperoxaluria may have different origins, from dietary
to genetic [57]. At the macroscopic scale, signiﬁcant dif-
ferences exist. Intermittent hyperoxaluria of dietary origin
corresponding to idiopathic stone formers leads to stones
with a dark-brown smooth or mammillary surface; for
primary hyperoxaluria [66e72] stones have a surface with
a mulberry-shaped aspect of cream or pale yellowebrown
color [57]. These different kinds of hyperoxaluria lead to the
same whewellite chemical phase.
To compare the structural characteristics of the stones at
the mesoscopic and nanometric scale, NPD and FE-SEM
studies were carried out [73]. The crystal structure of
whewellite was ﬁrst revisited using single-crystal neutronFig. 5. Different scattering diagrams collected on G4.1 on whewellite kidney
stones.
Fig. 6. Neutron diffractograms collected on G4.1 for struvite and calcium
phosphate apatite kidney stones.
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corresponding to different kinds of hyperoxaluria were
examined, at the mesoscopic scale with FE-SEM, and at the
nanometric scale with NPD (Fig. 5). The results show that,
although the various whewellite kidney stones exhibit
similar neutron diffraction patterns, signiﬁcant differences
exist at the mesoscopic scale, which explains the poly-
morphism of whewellite stones observed at the macro-
scopic scale. Combined NPD and FE-SEM datasets therefore
deﬁne a completely new medical diagnosis of primary
hyperoxaluria [74], a rare inherited disease, leading to
recurrent nephrolithiasis, nephrocalcinosis, systemic oxa-
losis, and renal failure, ultimately requiring combined
kidney and liver transplantation.
3.3. Struvite kidney stones
Unlike more common calcium kidney stones, struvite
stones [75e80] are formed by bacterial waste products
during a kidney or urinary tract infection (UTI). Struvite
kidney stones can lead to rapid obstruction, hydro-
nephrosis, recurrent pyelonephritis, and decreased kidney
function; owing to the urine decomposition process, large
(cm) kidney stones can grow over a period of a few weeks.
Urea-splitting bacteria such as Proteus, Staphylococcus,
Pseudomonas, Providencia, and Klebsiella generate struvite
kidney stones [81e83]. In addition, urease-negative bac-
teria like those with weak urease activity, such as some
strains of Escherichia coli, may also be involved in the for-
mation of struvite renal calculi, although urease-positive
bacteria seem to play a greater role. If these organisms
leave their imprints at the surface of kidney stones made of
apatite, the presence of such imprints has not been found at
the surface of struvite kidney stones. Moreover, in a stone
containing both carbonated apatite and struvite compo-
nents, bacterial imprints were observed on the carbonated
apatite but not on the struvite part.
NPD can provide an understanding of this apparent
contradiction between clinical data gathered at the hospital
and observations obtained through FE-SEM [84]. A typical
diffraction pattern collected for a struvite kidney stone is
compared in Fig. 6 with the pattern of an apatite kidney
stone. Even if the background level was high (owing to the
large hydrogen content of the biological samples), the high
quality of the signal-to-noise ratio allows one to perform a
complete Rietveld-type reﬁnement, with an analysis of the
crystallite size for both samples. While struvite kidney
stones consisted of quite large nanocrystals (250 nm), as
expected from the well-deﬁned diffraction peaks (Fig. 6),
crystallites in carbonated calcium phosphate apatite kidney
stones are much smaller, ~50 nm. To explain the absence of
bacterial imprints at the surface of struvite kidney stones,
an analogy with a manwalking on a beach can be drawn: if
the beach is made of sand, footprints may be observed, but
if the beach is made of stone, no footprints will be seen.
Therefore, a relationship between the size of bacteria and
the size of nanocrystals becomes relevant when looking for
bacterial imprints: bacterial imprints may appear with
small calcium carbonated apatite nanocrystals, rather than
with large struvite nanocrystals. This result obtained
through neutron diffraction has a major clinicalsigniﬁcance. Neutron diffraction diagrams validate an
approach in which infection leads to the presence of stru-
vite kidney stones or the presence of bacterial imprints at
the surface of Ca phosphate apatite even if infection is
asymptomatic. Indeed, for several patients without any
symptoms related to infection (negative urinary test, no
fever…) and which have kidney stones without struvite or
Ca apatite with a high carbonation rate, observations
through Field Emission Scanning Electron Microscopy (FE-
SEM) point out the presence of bacterial imprints. Antibi-
otic therapy starts immediately, avoiding major kidney
infection, which can lead to the loss of the kidney function
and thus to dialysis and kidney graft.3.4. Apatite kidney stones and ab initio simulation
Regarding nanometer scale particles, it is also possible
to build neutron (or X-ray) diffraction intensity I(q) through
Debye scattering [85e91].
IðqÞ ¼
X
i
X
j
biðqÞbjðqÞ

sin

qRij

qRij
In this equation, I(q) is the angle dependent intensity
from coherent scattering, the sums over i and j are over all
the atoms, Rij is the distance between the atoms i and j, and
bi and bj are the neutron scattering lengths of the different
atoms i and j. It is quite easy to build a structural model for
particles displaying different morphologies (cylinders,
spheres, etc.) and to calculate the scattering intensity. More
precisely, A. Guagliardi et al. [92] have used the hexagonal
P63/m structure [93e95] as the building block for con-
structing a family of nanocrystals.
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tering proﬁles for different particle shapes, andmatch them
to experimental data (Fig. 7, in the case of nanocrystals of
Ca phosphate apatite). The next step will be to study the
effect of other parameters, such as cationic substitution in
the nanocrystals investigated.4. Neutron scattering and bioceramics
Ceramics such as Al2O3/YeZrO2 [96] and Ca phosphates
[97e102], as well as bioactive glasses [103e105], are
extensively used in different kinds of prosthesis. Their
behaviour during manufacturing and in the human body is
therefore of great importance and a topic of extensive
research. Being able to understand and predict their
behaviour under stress or strain is a major challenge, which
can be achieved with neutron diffraction.
Regarding Ca phosphate, several investigations have
been performed on the Ca phosphate apatite using the
neutron probe. For example, based on inelastic neutron-
scattering experiments, C.K. Loong et al. [106] underlined
the lack of OH ions in the crystals of bone apatite. R.G. Hill
et al. [107] have investigated the early stages of nucleation
and crystallisation of an apatite (ﬂuorapatite, Ca5(PO4)3F).
P.C.H. Mitchell et al. [108] have assessed the localisation of
water in the apatite framework. More recently, D. Arcos
et al. [109,110] have investigated silicon doped hydroxy-
apatites (SiHA) by neutron diffraction. They have noticed an
enhanced disorder of the H atom belonging to the OH
groups in SiHA, which could contribute to the higher
reactivity of SiHA with respect to HA. Finally, combining
neutron scattering experiments and NMR, S. Gomes et al.
[111] have underlined the presence of two types of protons
in the Si-substituted HAp phase, the new site correspond-
ing to species engaged in hydrogen bonding with silicate
anions.Fig. 7. Scattering diagrams calculated following the Debye formulae for
different morphologies (cylinders and spherical) compared with experi-
mental data.5. Conclusion and perspectives
Using neutrons as probes allows clinicians to gather
information on trace elements [112], and to get structural
information, both at the atomic scale (crystal structure) and
at the crystallite scale (crystallite size). The fact that this
technique is non-destructive, and can investigate bulk el-
ements while preserving the physicochemical state of the
biological samples, constitutes a unique and precious
advantage. With the micro-beam instruments available at
the new European neutron source [113] and progress in
neutron tomography, mapping “bulk” biological samples
will also allow new types of investigations, like the struc-
tural characteristics of nanopathological calciﬁcations
embedded in tissues, for example. Neutron spectroscopy is
another technique that can be evoked, as it is already used
extensively in biology, to study, e.g., water dynamics in
cells, or protein unfolding.References
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